Corvus Pharmaceuticals, Inc. (CRVS) Tops Q3 EPS by 1c

Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) reported Q3 EPS of ($0.12), $0.01 better than the analyst estimate of ($0.13).

For earnings history and earnings-related data on Corvus Pharmaceuticals, Inc. (CRVS) click here.

You May Also Be Interested In

• Apollo Global Management (APO) call put ratio 1 call to 6.8 puts a focus on a spreader of 9K contracts January 95 and 135 puts
• FTI Consulting names Jerome Nyssen senior managing director in Australia
• Faraday Future reveals robot lineup and new products at Automate